Cardiovascular DiseasesPhase 4NCT00153101
Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo.
A Phase 4 study testing Telmisartan, Combination of Telmisartan and Ramipril and Ramipril in people with Cardiovascular Diseases, run by Boehringer Ingelheim at 732 sites in 41 countries.
Trial summary
The Ongoing Telmisartan Alone and in combination wiht Ramipril Global Endpoint trial (ONTARGET): The primary objectives are to determine if (a) telmisartan 80mg daily and ramipril 10mg daily combination therapy is more effective in reducing the composite endpoint of Cardiovascular Death (CV) death, Myocardial… Read more about this study
- Who is it for?
- Ages 55 years and older
- Conditions the study is for
- Cardiovascular Diseases
- What is being tested?
- Telmisartan, Combination of Telmisartan and Ramipril and Ramipril
- How many people
- 31,546 participants
- Where
- 732 sitesin 41 countries
- Study dates
- Nov 2001to Jun 2008
- Phase
- Phase 4
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 55 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Coronary Artery Disease: Previous Myocardial infarction(> 2 days prior to informed consent), or stable or previous unstable angina (> 30 days prior to informed consent) with documented multivessel coronary artery disease or a positive stress test, or multivessel Percutaneous Transluminal Coronary Angioplasty (> 30 days prior to informed consent), or previous multivessel Coronary Artery Bypass Grafting without angina (if surgery performed > 4 years prior to informed consent) or with recurrent angina after surgery.
- Other High Risk:
- Peripheral Arterial Disease: Previous limb bypass surgery or angioplasty or amputation, intermittent claudication on history with ankle/arm Blood Pressure ratio < 0.8 on at least one side, or significant stenosis by angiography or non-invasive testing
- Previous stroke
- Transient ischemic Attack > 7 days and < 1 year prior to informed consent
- Diabetes Mellitus (types I or II): with evidence of end-organ damage (retinopathy, Left ventricular hypertrophy, micro or macro albuminuria), or any evidence of previous cardiac or vascular disease.
- No definite and specific indication or contraindication for any of the study treatments. Written informed consent.
Who cannot join
- Medication use:
- Inability to discontinue Angiotension Converting Enzyme (ACE) inhibitors or Angiotension 2 receptor antagonists (AIIAs).
- Patients with known hypersensitivity or intolerance to Angiotension 2 receptor antagonists (AIIAs) or Angiotension Converting Enzyme (ACE)inhibitors.
- NOTE: Patients with known intolerance to Angiotension Converting Enzyme inhibitor intolerance ( ACE-I) can be enrolled in the TRANSCEND study.
- Cardiovascular disease:
- Symptomatic congestive heart failure.
Show all 29Show fewer
- Hemodynamically significant primary valvular or outflow tract obstruction (e.g. aortic or mitral valve stenosis, asymmetric septal hypertrophy, malfunctioning prosthetic valve).
- Constrictive pericarditis.
- Complex congenital heart disease.
- Syncopal episodes of unknown etiology < 3 months before informed consent.
- Planned cardiac surgery or angioplasty within three months.
- Uncontrolled hypertension on treatment (i.e.Blood pressure ( BP) > 160/100).
- Heart transplant recipient.
- Strokes due to subarachnoid hemorrhage
- Other conditions:
- Significant renal disease defined as:
- Renal artery stenosis;
- Creatinine clearance < 0.6 ml/min or serum creatinine > 265 umol/L (> 3.0 mg/dL);
- Hyperkalemia: potassium > 5.5 mmol/L.
- Proteinuria* (for TRANSCEND only).
- Hepatic dysfunction as defined by the following laboratory parameters: Serum Glutamate Pyruvate Transaminase( SGPT) Alaninaminotransferase (ALT) or Serum Glutamic Oxaloacetic Transaminase (SGOT) Aspartate aminotransferase (AST) > than 4 times upper limit of normal or additional criteria for hepatic impairment the upper limit of normal range, total Bilirubin > 20 umol/L, biliary obstructive disorders.
- Uncorrected volume depletion or sodium depletion.
- Primary aldosteronism.
- Hereditary fructose intolerance.
- Any other major non-cardiac illness expected to reduce life expectancy or interfere with study participation.
- Patient is simultaneously taking another experimental drug.
- Patient with significant disability that precludes regular attendance at clinic for follow-up.
- Patient has sufficient disability or other incapacity that precludes regular attendance at clinic for follow-up.
- Unable or unwilling to provide written informed consent.
Trial locations and contacts
732 sites in 41 countries.
732 sites in 41 countries
United States100 sites
502.373.0256 Boehringer Ingelheim Investigational Site
Athens, Alabama
502.373.0161 Boehringer Ingelheim Investigational Site
Augusta, Georgia
502.373.0193 Boehringer Ingelheim Investigational Site
Augusta, Georgia
502.373.0201 Boehringer Ingelheim Investigational Site
Augusta, Georgia
502.373.0247 Boehringer Ingelheim Investigational Site
Baltimore, Maryland
502.373.0209 Boehringer Ingelheim Investigational Site
Bentonville, Arkansas
502.373.0181 Boehringer Ingelheim Investigational Site
Biloxi, Mississippi
502.373.0251 Boehringer Ingelheim Investigational Site
Birmingham, Alabama
502.373.0284 Boehringer Ingelheim Investigational Site
Boston, Massachusetts
502.373.0226 Boehringer Ingelheim Investigational Site
Bridgeport, Connecticut
502.373.0213 Boehringer Ingelheim Investigational Site
Brooklyn, New York
502.373.0230 Boehringer Ingelheim Investigational Site
Buffalo, New York
502.373.0244 Boehringer Ingelheim Investigational Site
Burbank, Illinois
502.373.0249 Boehringer Ingelheim Investigational Site
Burke, Virginia
502.373.0157 Boehringer Ingelheim Investigational Site
Camden, New Jersey
502.373.0184 Boehringer Ingelheim Investigational Site
Charleston, South Carolina
502.373.0272 Boehringer Ingelheim Investigational Site
Chicago, Illinois
502.373.0155 Boehringer Ingelheim Investigational Site
Cincinnati, Ohio
502.373.0185 Boehringer Ingelheim Investigational Site
Cleveland, Mississippi
502.373.0164 Boehringer Ingelheim Investigational Site
Cleveland, Ohio
502.373.0248 Boehringer Ingelheim Investigational Site
Columbia, South Carolina
502.373.0173 Boehringer Ingelheim Investigational Site
Concord, California
502.373.0223 Boehringer Ingelheim Investigational Site
Conyers, Georgia
502.373.0172 Boehringer Ingelheim Investigational Site
Dallas, Texas
502.373.0187 Boehringer Ingelheim Investigational Site
Dallas, Texas
502.373.0219 Boehringer Ingelheim Investigational Site
Dallas, Texas
502.373.0275 Boehringer Ingelheim Investigational Site
Dallas, Texas
502.373.0168 Boehringer Ingelheim Investigational Site
Dayton, Ohio
502.373.0270 Boehringer Ingelheim Investigational Site
Des Moines, Iowa
502.373.0273 Boehringer Ingelheim Investigational Site
Durham, North Carolina
502.373.0202 Boehringer Ingelheim Investigational Site
East Orange, New Jersey
502.373.0265 Boehringer Ingelheim Investigational Site
Erie, Pennsylvania
502.373.0222 Boehringer Ingelheim Investigational Site
Fargo, North Dakota
502.373.0174 Boehringer Ingelheim Investigational Site
Farmington, Connecticut
502.373.0221 Boehringer Ingelheim Investigational Site
Fort Worth, Texas
502.373.0179 Boehringer Ingelheim Investigational Site
Gainesville, Florida
502.373.0259 Boehringer Ingelheim Investigational Site
Guthrie, Oklahoma
502.373.0266 Boehringer Ingelheim Investigational Site
Harbor City, California
502.373.0206 Boehringer Ingelheim Investigational Site
Houston, Texas
502.373.0234 Boehringer Ingelheim Investigational Site
Houston, Texas
502.373.0280 Boehringer Ingelheim Investigational Site
Houston, Texas
502.373.0254 Boehringer Ingelheim Investigational Site
Jackson, Mississippi
502.373.0195 Boehringer Ingelheim Investigational Site
Kansas City, Missouri
502.373.0288 Boehringer Ingelheim Investigational Site
Kingston, New York
502.373.0283 Boehringer Ingelheim Investigational Site
Loma Linda, California
502.373.0180 Boehringer Ingelheim Investigational Site
Los Angeles, California
502.373.0159 Boehringer Ingelheim Investigational Site
Mansfield, Ohio
502.373.0212 Boehringer Ingelheim Investigational Site
Milwaukee, Wisconsin
502.373.0208 Boehringer Ingelheim Investigational Site
Minneapolis, Minnesota
502.373.0232 Boehringer Ingelheim Investigational Site
Minneapolis, Minnesota
502.373.0167 Boehringer Ingelheim Investigational Site
Monroe, Louisiana
502.373.0238 Boehringer Ingelheim Investigational Site
New York, New York
502.373.0252 Boehringer Ingelheim Investigational Site
New York, New York
502.373.0286 Boehringer Ingelheim Investigational Site
New York, New York
502.373.0191 Boehringer Ingelheim Investigational Site
Newark, New Jersey
502.373.0169 Boehringer Ingelheim Investigational Site
North Las Vegas, Nevada
502.373.0166 Boehringer Ingelheim Investigational Site
Northport, New York
502.373.0178 Boehringer Ingelheim Investigational Site
Oklahoma City, Ohio
502.373.0154 Boehringer Ingelheim Investigational Site
Oklahoma City, Oklahoma
502.373.0217 Boehringer Ingelheim Investigational Site
Olympia Fields, Illinois
502.373.0279 Boehringer Ingelheim Investigational Site
Omaha, Nebraska
502.373.0183 Boehringer Ingelheim Investigational Site
Palm Harbor, Florida
502.373.0240 Boehringer Ingelheim Investigational Site
Panama City, Florida
502.373.0153 Boehringer Ingelheim Investigational Site
Philadelphia, Pennsylvania
502.373.0182 Boehringer Ingelheim Investigational Site
Phoenix, Arizona
502.373.0188 Boehringer Ingelheim Investigational Site
Phoenix, Arizona
502.373.0203 Boehringer Ingelheim Investigational Site
Pocatello, Idaho
502.373.0243 Boehringer Ingelheim Investigational Site
Portland, Oregon
502.373.0156 Boehringer Ingelheim Investigational Site
Rochester, New York
502.373.0264 Boehringer Ingelheim Investigational Site
Rochester, New York
502.373.0175 Boehringer Ingelheim Investigational Site
Sacramento, California
502.373.0231 Boehringer Ingelheim Investigational Site
Saint Paul, Minnesota
502.373.0165 Boehringer Ingelheim Investigational Site
San Diego, California
502.373.0228 Boehringer Ingelheim Investigational Site
San Leandro, California
502.373.0268 Boehringer Ingelheim Investigational Site
Sandersville, Georgia
502.373.0245 Boehringer Ingelheim Investigational Site
Savannah, Georgia
502.373.0227 Boehringer Ingelheim Investigational Site
Scarsdale, New York
502.373.0281 Boehringer Ingelheim Investigational Site
Seattle, Washington
502.373.0274 Boehringer Ingelheim Investigational Site
Sellersville, Pennsylvania
502.373.0158 Boehringer Ingelheim Investigational Site
Shreveport, Louisiana
502.373.0229 Boehringer Ingelheim Investigational Site
Springfield, Massachusetts
502.373.0207 Boehringer Ingelheim Investigational Site
St Louis, Missouri
502.373.0239 Boehringer Ingelheim Investigational Site
St Louis, Missouri
502.373.0205 Boehringer Ingelheim Investigational Site
Sylmar, California
502.373.0171 Boehringer Ingelheim Investigational Site
Tampa, Florida
502.373.0150 Boehringer Ingelheim Investigational Site
The Bronx, New York
502.373.0199 Boehringer Ingelheim Investigational Site
Tucker, Georgia
502.373.0189 Boehringer Ingelheim Investigational Site
Tucson, Arizona
502.373.0152 Boehringer Ingelheim Investigational Site
Tulsa, Oklahoma
502.373.0177 Boehringer Ingelheim Investigational Site
Tuscon, Arizona
502.373.0162 Boehringer Ingelheim Investigational Site
Valdosta, Georgia
502.373.0282 Boehringer Ingelheim Investigational Site
Vero Beach, Florida
502.373.0258 Boehringer Ingelheim Investigational Site
Washington D.C., District of Columbia
502.373.0277 Boehringer Ingelheim Investigational Site
West Hills, California
502.373.0163 Boehringer Ingelheim Investigational Site
Westfield, New York
502.373.0214 Boehringer Ingelheim Investigational Site
Weston, Florida
502.373.0271 Boehringer Ingelheim Investigational Site
Westwood, New Jersey
502.373.0241 Boehringer Ingelheim Investigational Site
Williamsville, New York
502.373.0261 Boehringer Ingelheim Investigational Site
Winston-Salem, North Carolina
502.373.0237 Boehringer Ingelheim Investigational Site
Wyandotte, Michigan
Canada74 sites
502.373.0056 Antigonish Clinical Trials
Antigonish Nova Scotia, Nova Scotia
502.373.0031 Brampton Research Associates
Brampton, Ontario
502.373.0001 C849 Division of Cardiology, Foothills Medical Centre
Calgary, Alberta
502.373.0071 Peter Lougheed Centre
Calgary, Alberta
502.373.0073 Alder Medical Centre
Campbell River, British Columbia
502.373.0062 Gain Medical Centre
Coquitlam, British Columbia
502.373.0020 CHA/University Hospital
Edmonton, Alberta
502.373.0081 Centre de recherche clinique, CUSE 3001
Fleurimont, Quebec
502.373.0076 Centre Hospitalier de Vallees de l'Outaouais Gatineau
Gatineau, Quebec
502.373.0007 Sudbury Cardiac Research
Greater Sudbury, Ontario
502.373.0045 Queen Elizabeth II HSC
Halifax, Nova Scotia
502.373.0011 St. Joseph's Hospital Cardiac Research
Hamilton, Ontario
502.373.0034 HGH McMaster Clinic
Hamilton, Ontario
502.373.0035 Hamilton Medical Research
Hamilton, Ontario
502.373.0064 Chedoke Hospital
Hamilton, Ontario
502.373.0082 3U4, McMaster University Medical Centre
Hamilton, Ontario
502.373.0085 HGH McMaster Clinic
Hamilton, Ontario
502.373.0046 Interior Clinical Research Consultants Ltd
Kelowna, British Columbia
502.373.0057 Centre De Recherche Clinique
Laval, Quebec
502.373.0033 Clinique de Cardiologie de Levis
Lévis, Quebec
502.373.0024 London HSC - University Hospital
London, Ontario
502.373.0010 Recherche Invascor
Longueuil, Quebec
502.373.0013 Suite 170
Longueuil, Quebec
502.373.0014 Via Car Recherche Clinique Inc
Longueuil, Quebec
502.373.0015 C/O Peter Carmichael
Longueuil, Quebec
502.373.0016 Suite 170
Longueuil, Quebec
502.373.0017 Suite 170
Longueuil, Quebec
502.373.0086 Via Car Recherche Clinique Inc
Longueuil, Quebec
502.373.0030 Portage Clinical Studies
Manitoba, Manitoba
502.373.0044 Mississauga Clinical Research Centre
Mississauga, Ontario
502.373.0018 Montreal Heart Institute
Montreal, Quebec
502.373.0021 Medi - recherche Inc.
Montreal, Quebec
502.373.0022 CHUM - Hotel Dieu
Montreal, Quebec
502.373.0025 Hopital Maisonneuve Rosemont
Montreal, Quebec
502.373.0079 Jewish General Hospital
Montreal, Quebec
502.373.0038 New West Cardiac Research
New Westminster, British Columbia
502.373.0043 Fraser Clinical Trial Inc
New Westminster, Ontario
502.373.0032 New Market Cardiology Research Grp
Newmarket, Ontario
502.373.0037 Niagara Falls Medical Centre
Niagara Falls, Ontario
502.373.0048 Suite 100
North Vancouver, British Columbia
502.373.0054 Orleans Medical-Dental Centre
Orléans, Ontario
502.373.0058 Medical Sciences Building
Oshawa, Ontario
502.373.0063 Paradigm Clinical Trials
Oshawa, Ontario
502.373.0029 Riverside Professional Building
Ottawa, Ontario
502.373.0051 Merivale Cardiovascular Consultants
Ottawa, Ontario
502.373.0002 Penticton Regional Hospital
Penticton, British Columbia
502.373.0028 Hop. Du St. Sacrement
Québec, Quebec
502.373.0041 Recherches Clinicar Inc.
Québec, Quebec
502.373.0080 Polyclinique vasculaire Centre hospitalier universitaire de
Québec, Quebec
502.373.0084 CHA-Hopital de l'Efant-Jesus
Québec, Quebec
502.373.0040 Etobicok Cardiology
Rexdale, Ontario
502.373.0027 Ctr Hospitalier Beauce Etchemin
Saint George de Beauce, Quebec
502.373.0050 St. Pierre Medical Clinic
Saint Pierre, Manitoba
502.373.0053 Mount Royal Clinic
Saskatoon, Saskatchewan
502.373.0055 Specialists - Internal Medicine
Saskatoon, Saskatchewan
502.373.0066 SDRI - University of Saskatchewan
Saskatoon, Saskatchewan
502.373.0067 SDRI - University of Saskatchewan
Saskatoon, Saskatchewan
502.373.0068 SDRI - University of Saskatchewan
Saskatoon, Saskatchewan
502.373.0070 SDRI - University of Saskatchewan
Saskatoon, Saskatchewan
502.373.0023 Group Health Centre - Clinical Trials
Sault Ste. Marie, Ontario
502.373.0039 Scarborough Cardiology Research
Scarborough Village, Ontario
502.373.0005 Dr. Jeffrey Hiscock
St. John's, Newfoundland and Labrador
502.373.0006 The General Hospital
St. John's, Newfoundland and Labrador
502.373.0012 Hopital Laval - Institute Cardiologie de Quebec
Ste-Foy, Quebec
502.373.0026 Centre hospitalier Pierre-Le Gardeur
Terrebonne, Quebec
502.373.0072 Chra
Thetford-Mines, Quebec
502.373.0061 CLIKS Medical Research Corp
Thunder Bay, Ontario
502.373.0042 Sunnybrook & Woman's College Health Science Centre
Toronto, Ontario
502.373.0083 St. Michael's Hospital
Toronto, Ontario
502.373.0009 Vancouver Hospital
Vancouver, British Columbia
502.373.0003 Discovery Clinical Services Ltd
Victoria, British Columbia
502.373.0052 Dr. Bruce Lubelsky
Willowdale, Ontario
502.373.0008 Windsor Health Clinic
Windsor, Ontario
502.373.0077 Health Science Centre Diabetes Research Group
Winnipeg, Manitoba
Germany35 sites
502.373.1164 Boehringer Ingelheim Investigational Site
Bad Lausick
502.373.1166 Boehringer Ingelheim Investigational Site
Bad Lauterberg im Harz
502.373.1138 Boehringer Ingelheim Investigational Site
Bad Mergentheim
502.373.1156 Boehringer Ingelheim Investigational Site
Berlin
502.373.1160 Boehringer Ingelheim Investigational Site
Berlin
502.373.1161 Boehringer Ingelheim Investigational Site
Berlin
502.373.1144 Boehringer Ingelheim Investigational Site
Bielefeld
502.373.1137 Boehringer Ingelheim Investigational Site
Cologne
502.373.1152 Boehringer Ingelheim Investigational Site
Dessau
502.373.1139 Boehringer Ingelheim Investigational Site
Dortmund
502.373.1159 Boehringer Ingelheim Investigational Site
Dortmund
502.373.1136 Boehringer Ingelheim Investigational Site
Dresden
502.373.1145 Boehringer Ingelheim Investigational Site
Eberswalde
502.373.1155 Boehringer Ingelheim Investigational Site
Erlangen
502.373.1157 Boehringer Ingelheim Investigational Site
Essen
502.373.1153 Boehringer Ingelheim Investigational Site
Haag
502.373.1148 Boehringer Ingelheim Investigational Site
Hamburg
502.373.1132 Boehringer Ingelheim Investigational Site
Heidelberg
502.373.1131 Boehringer Ingelheim Investigational Site
Homburg/Saar
502.373.1147 Boehringer Ingelheim Investigational Site
Karlsburg
502.373.1154 Boehringer Ingelheim Investigational Site
Kelkheim
502.373.1142 Boehringer Ingelheim Investigational Site
Künzing
502.373.1165 Boehringer Ingelheim Investigational Site
Lübeck
502.373.1134 Boehringer Ingelheim Investigational Site
Mainz
502.373.1133 Boehringer Ingelheim Investigational Site
Melsungen
502.373.1146 Boehringer Ingelheim Investigational Site
München
502.373.1149 Boehringer Ingelheim Investigational Site
Offenbach
502.373.1162 Boehringer Ingelheim Investigational Site
Riesa
502.373.1140 Boehringer Ingelheim Investigational Site
Rostock
502.373.1150 Boehringer Ingelheim Investigational Site
Sindelfingen
502.373.1163 Boehringer Ingelheim Investigational Site
Starnberg
502.373.1158 Boehringer Ingelheim Investigational Site
Stuttgart
502.373.1167 Boehringer Ingelheim Investigational Site
Timmendorfer Strand
502.373.1135 Boehringer Ingelheim Investigational Site
Wiesbaden
502.373.1141 Boehringer Ingelheim Investigational Site
Witten
Australia33 sites
502.373.0546 Flinders Medical Centre
Bedford Park, South Australia
502.373.0531 Box Hill Hospital
Box Hill, Victoria
502.373.0536 Royal Prince Alfred Hospital
Camperdown, New South Wales
502.373.0523 The Prince Charles Hospital
Chermside, Queensland
502.373.0544 Coffs Harbour Cardiovascular Clinic
Coffs Harbour, New South Wales
502.373.0538 Concord Repatriation General Hospital
Concord, New South Wales
502.373.0550 Repatriation General Hospital
Daw Park, South Australia
502.373.0548 The Northern Hospital
Epping, Victoria
502.373.0547 Fremantle Hospital
Fremantle, Western Australia
502.373.0522 The Geelong Hospital
Geelong, Victoria
502.373.0539 Central Coast Neuroscience Research
Gosford, New South Wales
502.373.0556 Gosford Hospital
Gosford, New South Wales
502.373.0524 Royal Brisbane Hospital
Herston, Queensland
502.373.0526 Peninsula Clinical Research Centre
Kippa-Ring, Queensland
502.373.0542 St. George Hospital
Kogarah, New South Wales
502.373.0552 St George Private Hospital
Kogarah, New South Wales
502.373.0559 St George Hospital - Dept of Clinical Pharmacology
Kogarah, New South Wales
502.373.0529 Launceston General Hospital
Launceston, Tasmania
502.373.0530 Sir Charles Gairdner Hospital
Nedlands, Western Australia
502.373.0528 John Hunter Hospital
Newcastle, New South Wales
502.373.0520 Royal Melbourne Hospital
Parkville, Victoria
502.373.0545 Royal Perth Hospital
Perth, Western Australia
502.373.0551 Port Lincoln "The Investigator" Clinic
Port Lincoln, South Australia
502.373.0525 The Alfred Hospital
Prahran, Victoria
502.373.0532 Baker Medical Research Centre
Prahran, Victoria
502.373.0535 The Prince of Wales Hospital
Randwick, New South Wales
502.373.0557 Maroondah Hospital
Ringwood East, Victoria
502.373.0540 Gold Coast Hospital
Southport, Queensland
502.373.0533 Royal North Shore Hospital
St Leonards, New South Wales
502.373.0537 Austin & Repatriation Medical Centre
West Heidelberg, Victoria
502.373.0534 The Canberra Hospital
Woden, Australian Capital Territory
502.373.0549 Illawarra Regional Hospital
Wollongong, New South Wales
502.373.0521 Princess Alexandra Hospital
Woolloongabba, Queensland
China33 sites
502.373.0601 Boehringer Ingelheim Investigational Site
Beijing
502.373.0602 Boehringer Ingelheim Investigational Site
Beijing
502.373.0603 Boehringer Ingelheim Investigational Site
Beijing
502.373.0604 Boehringer Ingelheim Investigational Site
Beijing
502.373.0605 Boehringer Ingelheim Investigational Site
Beijing
502.373.0606 Boehringer Ingelheim Investigational Site
Beijing
502.373.0607 Boehringer Ingelheim Investigational Site
Beijing
502.373.0621 Boehringer Ingelheim Investigational Site
Beijing
502.373.0622 Boehringer Ingelheim Investigational Site
Beijing
502.373.0623 Boehringer Ingelheim Investigational Site
Beijing
502.373.0626 Boehringer Ingelheim Investigational Site
Beijing
502.373.0616 Boehringer Ingelheim Investigational Site
Changsha
502.373.0613 Boehringer Ingelheim Investigational Site
Chengdu
502.373.0625 Boehringer Ingelheim Investigational Site
Chengdu
502.373.0620 Boehringer Ingelheim Investigational Site
Guangzhou
502.373.0612 Boehringer Ingelheim Investigational Site
Harbin
502.373.0634 Boehringer Ingelheim Investigational Site
HeBei Province
502.373.0624 Boehringer Ingelheim Investigational Site
Henan Province
502.373.0627 Boehringer Ingelheim Investigational Site
Hubei Province
502.373.0614 Boehringer Ingelheim Investigational Site
Nanjing
502.373.0629 Boehringer Ingelheim Investigational Site
Qingdao
502.373.0632 Boehringer Ingelheim Investigational Site
ShanDong Province
502.373.0633 Boehringer Ingelheim Investigational Site
ShanDong Province
502.373.0617 Boehringer Ingelheim Investigational Site
Shanghai
502.373.0618 Boehringer Ingelheim Investigational Site
Shanghai
502.373.0619 Boehringer Ingelheim Investigational Site
Shanghai
502.373.0628 Boehringer Ingelheim Investigational Site
Shenyang
502.373.0611 Boehringer Ingelheim Investigational Site
Shijiazhuang
502.373.0615 Boehringer Ingelheim Investigational Site
Tianjin
502.373.0631 Boehringer Ingelheim Investigational Site
Tianjin
502.373.0630 Boehringer Ingelheim Investigational Site
Weizikeng
502.373.0608 Boehringer Ingelheim Investigational Site
Wuhan
502.373.0610 Boehringer Ingelheim Investigational Site
Zhenzhou
Italy30 sites
502.373.1257 Ospedale "Mazzoni"
Ascoli Piceno
502.373.1259 Ospedale di Bentivoglio
Bentivoglio (BO)
502.373.1255 Ospedale "S. Orsola Malpighi"
Bologna
502.373.1278 Ospedale Bellaria
Bologna
502.373.1275 A.O. Spedali Civili di Brescia -Univ. degli studi di Brescia
Brescia
502.373.1261 Ospedale Civile di Casarano
Casarano (LE)
502.373.1252 Azienda Ospedaliera di Caserta
Caserta
502.373.1254 Ospedale di Città della Pieve
Città Della Pieve (PG)
502.373.1262 Arcispedale "S. Anna"
Ferrara
502.373.1250 Ospedale Civile "S. Polo"
Monfalcone (go)
502.373.1266 Azienda Universitaria Policlinico "Federico II"
Naples
502.373.1267 Azienda Universitaria Policlinico II
Naples
502.373.1269 Università Federico II
Naples
502.373.1279 Asl Na 1
Naples
502.373.1264 Presidio Ospedaliero "Villa Sofia"
Palermo
502.373.1265 IRCCS - Policlinico S. Matteo
Pavia
502.373.1251 Policlinico Monteluce
Perugia
502.373.1258 Ospedale "R. Silvestrini"
Perugia
502.373.1274 Ospedale "R. Silvestrini"
Perugia
502.373.1253 Istituto di Ricovero a Carattere Scientifico Neuromed- IRCCS
Pozzilli (IS)
502.373.1263 Policlinico Umberto I
Roma
502.373.1268 Ospedale "S. Spirito"
Roma
502.373.1270 Policlinico di Tor Vergata
Roma
502.373.1273 A.O. "S. Camillo de Lellis"
Roma
502.373.1260 Ospedale "N. Melli"
S. Pietro Vernotico (BR)
502.373.1256 Ospedale Civile SS. Annunziata - USL 1
Sassari
502.373.1277 A.S.O. "S. Giovanni Battista"
Torino
502.373.1272 Ospedale di Circolo di Varese
Varese
502.373.1271 Ospedale Civile
Venezia
502.373.1276 Ospedale Belcolle
Viterbo
Brazil26 sites
502.373.405 Boehringer Ingelheim Investigational Site
Belo Horizonte
502.373.412 Boehringer Ingelheim Investigational Site
Belo Horizonte
502.373.426 Boehringer Ingelheim Investigational Site
Belo Horizonte
502.373.418 Boehringer Ingelheim Investigational Site
Botucatu
502.373.407 Boehringer Ingelheim Investigational Site
Campinas
502.373.419 Boehringer Ingelheim Investigational Site
Campinas
502.373.425 Boehringer Ingelheim Investigational Site
Cerqueira César - São Paulo
502.373.406 Boehringer Ingelheim Investigational Site
Curitiba
502.373.411 Boehringer Ingelheim Investigational Site
Goiânia
502.373.403 Boehringer Ingelheim Investigational Site
Marília
502.373.400 Boehringer Ingelheim Investigational Site
Pelotas
502.373.416 Boehringer Ingelheim Investigational Site
Porto Alegre
502.373.417 Boehringer Ingelheim Investigational Site
Porto Alegre
502.373.415 Boehringer Ingelheim Investigational Site
Porto Alegre - Rs
502.373.420 Boehringer Ingelheim Investigational Site
Ribeirão Preto
502.373.414 Boehringer Ingelheim Investigational Site
Rio de Janeiro
502.373.413 Boehringer Ingelheim Investigational Site
Rio de Janeiro - Rj
502.373.409 Boehringer Ingelheim Investigational Site
Salvador
502.373.410 Boehringer Ingelheim Investigational Site
Salvador
502.373.404 Boehringer Ingelheim Investigational Site
Santa Catalina
502.373.421 Boehringer Ingelheim Investigational Site
São José do Rio Preto
502.373.402 Boehringer Ingelheim Investigational Site
São Paulo
502.373.408 Boehringer Ingelheim Investigational Site
São Paulo
502.373.422 Boehringer Ingelheim Investigational Site
São Paulo
502.373.424 Boehringer Ingelheim Investigational Site
São Paulo
502.373.423 Boehringer Ingelheim Investigational Site
Vila Clementino, São Paulo
France25 sites
502.373.1093 Cabinet Médical
Albens
502.373.1090 Cabinet Médical
Béziers
502.373.1075 Cabinet Médical
Bourges
502.373.1091 Cabinet Médical
Broglie
502.373.1097 Cabinet Médical
Castelnaudary
502.373.1089 Cabinet Médical
Gémenos
502.373.1099 Cabinet Médical
Husseren Wesserlin
502.373.1094 Cabinet Médical
Hyères
502.373.1078 Cabinet Médical des Tanneurs
L'Aigle
502.373.1096 Cabinet Médical
La Rochelle
502.373.1081 Cabinet Médical
Le Pradet
502.373.1083 Cabinet Médical
Mûrs-Erigné
502.373.1084 Cabinet Médical
Nantes
502.373.1086 Cabinet Médical
Nantes
502.373.1080 Cabinet Médical
Niort
502.373.1095 Cabinet Médical
Orthez
502.373.1079 Cabinet Médical
Paris
502.373.1088 Cabinet Médical
Rennes
502.373.1098 Cabinet Médical
Rosiers-d'Égletons
502.373.1076 Cabinet Médical La Grande Ramée
Saint Martin dHyeres
502.373.1085 Cabinet Médical
Saint-Julien-des-Landes
502.373.1092 Cabinet Médical de St Pierre
Saint-Pierre-de-Chandieu
502.373.1077 Cabinet Médical
Saint-Romain-sur-Cher
502.373.1087 Cabinet Médical
Strasbourg
502.373.1082 Cabinet Médical
Tours
Poland25 sites
502.373.1354 Boehringer Ingelheim Investigational Site
Bydgoszcz
502.373.1366 Boehringer Ingelheim Investigational Site
Częstochowa
502.373.1368 Boehringer Ingelheim Investigational Site
Gdynia
502.373.1365 Boehringer Ingelheim Investigational Site
Gdynia Redlowo
502.373.1359 Boehringer Ingelheim Investigational Site
Grójec
502.373.1369 Boehringer Ingelheim Investigational Site
Grudziądz
502.373.1375 Boehringer Ingelheim Investigational Site
Inowrocław
502.373.1360 Boehringer Ingelheim Investigational Site
Jarosławiec
502.373.1372 Boehringer Ingelheim Investigational Site
Katowice
502.373.1376 Boehringer Ingelheim Investigational Site
Katowice
502.373.1361 Boehringer Ingelheim Investigational Site
Kielce
502.373.1358 Boehringer Ingelheim Investigational Site
Lodz
502.373.1364 Boehringer Ingelheim Investigational Site
Lubartów
502.373.1374 Boehringer Ingelheim Investigational Site
Lubin
502.373.1367 Boehringer Ingelheim Investigational Site
Nowy Sącz
502.373.1356 Boehringer Ingelheim Investigational Site
Piotrkow Trybunalski
502.373.1370 Boehringer Ingelheim Investigational Site
Poznan
502.373.1357 Boehringer Ingelheim Investigational Site
Ruda Śląska
502.373.1352 Boehringer Ingelheim Investigational Site
Skierniewice
502.373.1362 Boehringer Ingelheim Investigational Site
Tarnów
502.373.1355 Boehringer Ingelheim Investigational Site
Tomaszów Mazowiecki
502.373.1353 Boehringer Ingelheim Investigational Site
Torun
502.373.1351 Boehringer Ingelheim Investigational Site
Warsaw
502.373.1363 Boehringer Ingelheim Investigational Site
Warsaw
502.373.1373 Boehringer Ingelheim Investigational Site
Węgrów
Argentina24 sites
502.373.350 Boehringer Ingelheim Investigational Site
Capital Federal
502.373.351 Boehringer Ingelheim Investigational Site
Capital Federal
502.373.352 Boehringer Ingelheim Investigational Site
Capital Federal
502.373.353 Boehringer Ingelheim Investigational Site
Capital Federal
502.373.354 Boehringer Ingelheim Investigational Site
Capital Federal
502.373.355 Boehringer Ingelheim Investigational Site
Capital Federal
502.373.356 Boehringer Ingelheim Investigational Site
Capital Federal
502.373.378 Boehringer Ingelheim Investigational Site
Capital Federal
502.373.357 Boehringer Ingelheim Investigational Site
Córdoba
502.373.358 Boehringer Ingelheim Investigational Site
Córdoba
502.373.360 Boehringer Ingelheim Investigational Site
Córdoba
502.373.361 Boehringer Ingelheim Investigational Site
Córdoba
502.373.377 Boehringer Ingelheim Investigational Site
Córdoba
502.373.362 Boehringer Ingelheim Investigational Site
Corones Suárez
502.373.364 Boehringer Ingelheim Investigational Site
La Plata
502.373.365 Boehringer Ingelheim Investigational Site
Mar del Plata
502.373.366 Boehringer Ingelheim Investigational Site
Mendoza
502.373.376 Boehringer Ingelheim Investigational Site
Mendoza
502.373.367 Boehringer Ingelheim Investigational Site
Rosario
502.373.369 Boehringer Ingelheim Investigational Site
Salta
502.373.371 Boehringer Ingelheim Investigational Site
San Miguel de Tucumán
502.373.373 Boehringer Ingelheim Investigational Site
San Miguel de Tucumán
502.373.375 Boehringer Ingelheim Investigational Site
Santa Fe
502.373.374 Boehringer Ingelheim Investigational Site
Zárate
Netherlands23 sites
502.373.1313 Boehringer Ingelheim Investigational Site
's-Hertogenbosch
502.373.1309 Boehringer Ingelheim Investigational Site
Amsterdam
502.373.1305 Boehringer Ingelheim Investigational Site
Beverwijk
502.373.1302 Boehringer Ingelheim Investigational Site
Doetinchem
502.373.1304 Boehringer Ingelheim Investigational Site
Drachten
502.373.1301 Boehringer Ingelheim Investigational Site
Eindhoven
502.373.1318 Boehringer Ingelheim Investigational Site
Ermelo
502.373.1320 Boehringer Ingelheim Investigational Site
Ewijk
502.373.1310 Boehringer Ingelheim Investigational Site
Hengelo
502.373.1303 Boehringer Ingelheim Investigational Site
Hoorn
502.373.1322 Boehringer Ingelheim Investigational Site
Huizen
502.373.1300 Boehringer Ingelheim Investigational Site
Lichtenvoorde
502.373.1323 Boehringer Ingelheim Investigational Site
Losser
502.373.1307 Boehringer Ingelheim Investigational Site
Nieuwegein
502.373.1317 Boehringer Ingelheim Investigational Site
Rijswijk
502.373.1319 Boehringer Ingelheim Investigational Site
Roelofarendsveen
502.373.1308 Boehringer Ingelheim Investigational Site
Rotterdam
502.373.1321 Boehringer Ingelheim Investigational Site
Spijkenisse
502.373.1311 Boehringer Ingelheim Investigational Site
Stadskanaal
502.373.1312 Boehringer Ingelheim Investigational Site
The Hague
502.373.1314 Boehringer Ingelheim Investigational Site
Tilburg
502.373.1316 Boehringer Ingelheim Investigational Site
Utrecht
502.373.1315 Boehringer Ingelheim Investigational Site
Velp
Spain23 sites
502.373.1582 Boehringer Ingelheim Investigational Site
Alcorcón (Madrid)
502.373.1601 Boehringer Ingelheim Investigational Site
Alicante
502.373.1586 Boehringer Ingelheim Investigational Site
Barcelona
502.373.1590 Boehringer Ingelheim Investigational Site
Barcelona
502.373.1597 Boehringer Ingelheim Investigational Site
Barcelona
502.373.1599 Boehringer Ingelheim Investigational Site
Barcelona
502.373.1595 Boehringer Ingelheim Investigational Site
Burjasot (Valencia)
502.373.1584 Boehringer Ingelheim Investigational Site
Granada
502.373.1585 Boehringer Ingelheim Investigational Site
Granada
502.373.1576 Boehringer Ingelheim Investigational Site
Madrid
502.373.1578 Boehringer Ingelheim Investigational Site
Madrid
502.373.1580 Boehringer Ingelheim Investigational Site
Madrid
502.373.1589 Boehringer Ingelheim Investigational Site
Madrid
502.373.1592 Boehringer Ingelheim Investigational Site
Madrid
502.373.1577 Boehringer Ingelheim Investigational Site
Málaga
502.373.1596 Boehringer Ingelheim Investigational Site
Málaga
502.373.1594 Boehringer Ingelheim Investigational Site
Murcia
502.373.1579 Boehringer Ingelheim Investigational Site
Santiago de Compostela
502.373.1593 Boehringer Ingelheim Investigational Site
Santiago de Compostela
502.373.1598 Boehringer Ingelheim Investigational Site
Santiago de Compostela
502.373.1583 Boehringer Ingelheim Investigational Site
Seville
502.373.1575 Boehringer Ingelheim Investigational Site
Valencia
502.373.1591 Boehringer Ingelheim Investigational Site
Valencia
United Kingdom21 sites
502.373.1698 Boehringer Ingelheim Investigational Site
Aberdeen
502.373.1706 Boehringer Ingelheim Investigational Site
Bathampton
502.373.1690 Boehringer Ingelheim Investigational Site
Belfast
502.373.1694 Boehringer Ingelheim Investigational Site
Birmingham
502.373.1707 Boehringer Ingelheim Investigational Site
Brighton
502.373.1703 Boehringer Ingelheim Investigational Site
Cardiff
502.373.1709 Boehringer Ingelheim Investigational Site
Chichester
502.373.1701 Boehringer Ingelheim Investigational Site
Derby
502.373.1705 Boehringer Ingelheim Investigational Site
Gateshead
502.373.1710 Boehringer Ingelheim Investigational Site
Glasgow
502.373.1700 Boehringer Ingelheim Investigational Site
Kirkcaldy, Fife
502.373.1691 Boehringer Ingelheim Investigational Site
Leeds
502.373.1699 Boehringer Ingelheim Investigational Site
Leicester
502.373.1702 Boehringer Ingelheim Investigational Site
Lincoln
502.373.1697 Boehringer Ingelheim Investigational Site
Liverpool
502.373.1695 Boehringer Ingelheim Investigational Site
London
502.373.1693 Boehringer Ingelheim Investigational Site
Manchester
502.373.1708 Boehringer Ingelheim Investigational Site
Portadown, County Atrim
502.373.1692 Boehringer Ingelheim Investigational Site
Rugby
502.373.1696 Boehringer Ingelheim Investigational Site
Sheffield
502.373.1704 Boehringer Ingelheim Investigational Site
Stirling
Belgium20 sites
502.373.1004 Boehringer Ingelheim Investigational Site
Aalst
502.373.1015 Boehringer Ingelheim Investigational Site
Anderlecht
502.373.1005 Boehringer Ingelheim Investigational Site
Antwerp
502.373.1022 Boehringer Ingelheim Investigational Site
Bornem
502.373.1021 Boehringer Ingelheim Investigational Site
Brasschaat
502.373.1003 Boehringer Ingelheim Investigational Site
Bruges
502.373.1017 Boehringer Ingelheim Investigational Site
Charleroi
502.373.1009 Boehringer Ingelheim Investigational Site
Genk
502.373.1018 Boehringer Ingelheim Investigational Site
Godinne
502.373.1011 Boehringer Ingelheim Investigational Site
Haine-Saint-Paul
502.373.1019 Boehringer Ingelheim Investigational Site
Haine-Saint-Paul
502.373.1007 Boehringer Ingelheim Investigational Site
Hasselt
502.373.1000 Boehringer Ingelheim Investigational Site
Leuven
502.373.1020 Boehringer Ingelheim Investigational Site
Mechelen
502.373.1006 Boehringer Ingelheim Investigational Site
Mol
502.373.1028 Boehringer Ingelheim Investigational Site
Roeselare
502.373.1014 Boehringer Ingelheim Investigational Site
Seraing
502.373.1002 Boehringer Ingelheim Investigational Site
Turnhout
502.373.1010 Boehringer Ingelheim Investigational Site
Turnhout
502.373.1025 Boehringer Ingelheim Investigational Site
Woluwé-Saint-Lambert
Hungary20 sites
502.373.1227 Boehringer Ingelheim Investigational Site
Budapest
502.373.1230 Boehringer Ingelheim Investigational Site
Budapest
502.373.1231 Boehringer Ingelheim Investigational Site
Budapest
502.373.1232 Boehringer Ingelheim Investigational Site
Budapest
502.373.1233 Boehringer Ingelheim Investigational Site
Budapest
502.373.1235 Boehringer Ingelheim Investigational Site
Budapest
502.373.1237 Boehringer Ingelheim Investigational Site
Budapest
502.373.1239 Boehringer Ingelheim Investigational Site
Budapest
502.373.1242 Boehringer Ingelheim Investigational Site
Budapest
502.373.1244 Boehringer Ingelheim Investigational Site
Budapest
502.373.1236 Boehringer Ingelheim Investigational Site
Debrecen
502.373.1240 Boehringer Ingelheim Investigational Site
Debrecen
502.373.1228 Boehringer Ingelheim Investigational Site
Kecskemét
502.373.1241 Boehringer Ingelheim Investigational Site
Nyíregyháza
502.373.1226 Boehringer Ingelheim Investigational Site
Pécs
502.373.1229 Boehringer Ingelheim Investigational Site
Siófok
502.373.1238 Boehringer Ingelheim Investigational Site
Szeged
502.373.1225 Boehringer Ingelheim Investigational Site
Székesfehérvár
502.373.1234 Boehringer Ingelheim Investigational Site
Tatabánya
502.373.1243 Boehringer Ingelheim Investigational Site
Veszprém
Greece15 sites
502.373.1200 Boehringer Ingelheim Investigational Site
Athens
502.373.1203 Boehringer Ingelheim Investigational Site
Athens
502.373.1206 Boehringer Ingelheim Investigational Site
Athens
502.373.1207 Boehringer Ingelheim Investigational Site
Athens
502.373.1208 Boehringer Ingelheim Investigational Site
Athens
502.373.1214 Boehringer Ingelheim Investigational Site
Athens
502.373.1224 Boehringer Ingelheim Investigational Site
Corinth
502.373.1209 Boehringer Ingelheim Investigational Site
Elefsina
502.373.1211 Boehringer Ingelheim Investigational Site
Goudi/ Athens
502.373.1201 Boehringer Ingelheim Investigational Site
Ioannina
502.373.1210 Boehringer Ingelheim Investigational Site
Kavala,greece
502.373.1202 Boehringer Ingelheim Investigational Site
Melissia, Athens
502.373.1205 Boehringer Ingelheim Investigational Site
Thessaloniki
502.373.1213 Boehringer Ingelheim Investigational Site
Thessaloniki
502.373.1204 Boehringer Ingelheim Investigational Site
Véria
South Africa15 sites
502.373.1553 Boehringer Ingelheim Investigational Site
Bellville
502.373.1552 Boehringer Ingelheim Investigational Site
Bloemfontein
502.373.1550 Boehringer Ingelheim Investigational Site
Cape Town
502.373.1561 Boehringer Ingelheim Investigational Site
Cape Town
502.373.1551 Boehringer Ingelheim Investigational Site
Durban
502.373.1560 Boehringer Ingelheim Investigational Site
Fiachrdtpark, Bloemfontein
502.373.1563 Boehringer Ingelheim Investigational Site
George East
502.373.1554 Boehringer Ingelheim Investigational Site
KwaKhangela
502.373.1555 Boehringer Ingelheim Investigational Site
Park Town West
502.373.1559 Boehringer Ingelheim Investigational Site
Port Elizabeth
502.373.1562 Boehringer Ingelheim Investigational Site
Port Elizabeth
502.373.1558 Boehringer Ingelheim Investigational Site
Soweto
502.373.1557 Boehringer Ingelheim Investigational Site
Sunninghill
502.373.1564 Boehringer Ingelheim Investigational Site
Sunninghill
502.373.1556 Boehringer Ingelheim Investigational Site
Vanderbijlpark
Denmark12 sites
502.373.1450 Boehringer Ingelheim Investigational Site
Aalborg
502.373.1453 Boehringer Ingelheim Investigational Site
Aarhus C
502.373.1460 Boehringer Ingelheim Investigational Site
Elsinore
502.373.1455 Boehringer Ingelheim Investigational Site
Frederiksberg
502.373.1459 Boehringer Ingelheim Investigational Site
Frederiksberg C
502.373.1458 Boehringer Ingelheim Investigational Site
Hilleroed
502.373.1451 Boehringer Ingelheim Investigational Site
Holbæk
502.373.1452 Boehringer Ingelheim Investigational Site
Hvidovre
502.373.1461 Boehringer Ingelheim Investigational Site
Kjellerup
502.373.1456 Boehringer Ingelheim Investigational Site
Randers
502.373.1457 Boehringer Ingelheim Investigational Site
Slagelse
502.373.1454 Boehringer Ingelheim Investigational Site
Svendborg
Mexico12 sites
502.373.0450 Boehringer Ingelheim Investigational Site
Guadalajara
502.373.0451 Boehringer Ingelheim Investigational Site
Guadalajara
502.373.0452 Boehringer Ingelheim Investigational Site
Guadalajara
502.373.0459 Boehringer Ingelheim Investigational Site
Guadalajara
502.373.0460 Boehringer Ingelheim Investigational Site
Guadalajara
502.373.0461 Boehringer Ingelheim Investigational Site
Guadalajara
502.373.0470 Boehringer Ingelheim Investigational Site
Guadalajara
502.373.0457 Boehringer Ingelheim Investigational Site
México
502.373.0458 Boehringer Ingelheim Investigational Site
México
502.373.0454 Boehringer Ingelheim Investigational Site
Monterrey
502.373.0453 Boehringer Ingelheim Investigational Site
Zapopan
502.373.0456 Boehringer Ingelheim Investigational Site
Zapopan
Sweden12 sites
502.373.1504 Capio Lundby sjukhus
Gothenburg
502.373.1509 Hjärtsektionen / Med.kliniken
Gothenburg
502.373.1514 Hjärt/Kärlforskn.enheten
Gothenburg
502.373.1501 Hjaertmottagningen
Helsingborg
502.373.1505 Jakobsbergs sjukhus
Järfälla
502.373.1502 Borgmästargaardens Läkarmottagning
Malmö
502.373.1506 Hjärtmottagningen
Malmö
502.373.1507 Kardiologiska kliniken
Malmö
502.373.1508 Kolgahuset Läkargrupp
Malmö
502.373.1511 Sjuntorps Vaardcentral
Sjuntorp
502.373.1503 Källtorps Vaardcentral
Trollhättan
502.373.1512 Vännäs Vaardcentral
Vännäs
Czechia10 sites
502.373.1053 Boehringer Ingelheim Investigational Site
Brno
502.373.1060 Boehringer Ingelheim Investigational Site
Havířov
502.373.1055 Boehringer Ingelheim Investigational Site
Kladno
502.373.1059 Boehringer Ingelheim Investigational Site
Mladá Boleslav
502.373.1061 Boehringer Ingelheim Investigational Site
Pilsen
502.373.1051 Boehringer Ingelheim Investigational Site
Prague
502.373.1057 Boehringer Ingelheim Investigational Site
Prague
502.373.1062 Boehringer Ingelheim Investigational Site
Prague
502.373.1056 Boehringer Ingelheim Investigational Site
Příbram
502.373.1058 Boehringer Ingelheim Investigational Site
Ústí nad Orlicí
Finland10 sites
502.373.1486 Boehringer Ingelheim Investigational Site
Hämeenlinna
502.373.1470 Boehringer Ingelheim Investigational Site
Helsinki
502.373.1473 Boehringer Ingelheim Investigational Site
Helsinki
502.373.1479 Boehringer Ingelheim Investigational Site
Jyväskylä
502.373.1488 Boehringer Ingelheim Investigational Site
Kuopio
502.373.1481 Boehringer Ingelheim Investigational Site
Kuusankoski
502.373.1487 Boehringer Ingelheim Investigational Site
Liperi
502.373.1475 Boehringer Ingelheim Investigational Site
Oulun Kaupunki
502.373.1471 Boehringer Ingelheim Investigational Site
Turku
502.373.1485 Boehringer Ingelheim Investigational Site
Vantaa
Portugal10 sites
502.373.1402 Hospital Garcia de Orta
Almada
502.373.1400 Hospital Fernando Fonseca
Amadora
502.373.1411 Hospital de Santa Cruz
Carnaxide, 2799-523
502.373.1408 Hospitais da Universidade de Coimbra
Coimbra
502.373.1406 Hospital Distrital de Faro Geral
Faro
502.373.1403 Hospital de Santa Marta
Lisbon
502.373.1409 Hospital de Santa Maria
Lisbon
502.373.1401 Unidade Local de Saúde de Matosinhos
Matosinhos Municipality
502.373.1410 Hospital de Santo António
Porto
502.373.1407 Centro Hospitalar vila Nova de Gaia
Vila Nova de Gaia
South Korea10 sites
502.373.0763 Boehringer Ingelheim Investigational Site
Incheon
502.373.0764 Boehringer Ingelheim Investigational Site
Kwangju
502.373.0755 Boehringer Ingelheim Investigational Site
Pusan
502.373.0750 Boehringer Ingelheim Investigational Site
Seoul
502.373.0753 Boehringer Ingelheim Investigational Site
Seoul
502.373.0756 Boehringer Ingelheim Investigational Site
Seoul
502.373.0757 Boehringer Ingelheim Investigational Site
Seoul
502.373.0760 Boehringer Ingelheim Investigational Site
Seoul
502.373.0761 Boehringer Ingelheim Investigational Site
Seoul
502.373.0754 Boehringer Ingelheim Investigational Site
Taegu
Switzerland10 sites
502.373.1625 Boehringer Ingelheim Investigational Site
Basel
502.373.1632 Boehringer Ingelheim Investigational Site
Bellinzona
502.373.1634 Boehringer Ingelheim Investigational Site
Bern
502.373.1627 Boehringer Ingelheim Investigational Site
Biel/Bienne
502.373.1631 Boehringer Ingelheim Investigational Site
Chur
502.373.1633 Boehringer Ingelheim Investigational Site
Kreuzlingen
502.373.1639 Boehringer Ingelheim Investigational Site
Lausanne
502.373.1629 Boehringer Ingelheim Investigational Site
Lugano
502.373.1628 Boehringer Ingelheim Investigational Site
Sankt Gallen
502.373.1637 Boehringer Ingelheim Investigational Site
Zurich
Turkey (Türkiye)10 sites
502.373.1651 Cukurova Universitesi Tip Fakultesi
Adana
502.373.1652 Cukurova Universitesi Tip Fakultesi
Adana
502.373.1653 Ankara Hastanesi Endokrinoloji Bölümü
Ankara
502.373.1656 Baskent Universitesi Tip Fakultesi
Ankara
502.373.1659 Ankara Universitesi Tip Fakultesi
Ankara
502.373.1654 Göztepe SSK Egitim ve Arastirma Hastanesi
Istanbul
502.373.1655 Cerrahpasa Universitesi Tip Fakultesi
Istanbul
502.373.1657 Haseki Hastanesi
Istanbul
502.373.1658 Ege Universitesi Tip Fakultesi
Izmir
502.373.1650 Erciyes Universitesi Tip Fakultesi Kardiyoloji Anabilim Dali
Kayseri
Ukraine10 sites
502.373.1730 Boehringer Ingelheim Investigational Site
Dnyepropetrovsk
502.373.1731 Boehringer Ingelheim Investigational Site
Dnyepropetrovsk
502.373.1728 Boehringer Ingelheim Investigational Site
Kharkiv
502.373.1732 Boehringer Ingelheim Investigational Site
Kharkiv
502.373.1733 Boehringer Ingelheim Investigational Site
Kharkiv
502.373.1725 Boehringer Ingelheim Investigational Site
Kiev
502.373.1726 Boehringer Ingelheim Investigational Site
Kiev
502.373.1727 Boehringer Ingelheim Investigational Site
Kiev
502.373.1729 Boehringer Ingelheim Investigational Site
Kiev
502.373.1734 Boehringer Ingelheim Investigational Site
Kiev
Russia9 sites
502.373.1425 Boehringer Ingelheim Investigational Site
Moscow
502.373.1426 Boehringer Ingelheim Investigational Site
Moscow
502.373.1427 Boehringer Ingelheim Investigational Site
Moscow
502.373.1428 Boehringer Ingelheim Investigational Site
Moscow
502.373.1429 Boehringer Ingelheim Investigational Site
Moscow
502.373.1430 Boehringer Ingelheim Investigational Site
Moscow
502.373.1433 Boehringer Ingelheim Investigational Site
Moscow
502.373.1431 Boehringer Ingelheim Investigational Site
Saint Petersburg
502.373.1432 Boehringer Ingelheim Investigational Site
Saint Petersburg
Taiwan9 sites
502.373.0780 Boehringer Ingelheim Investigational Site
Changhua
502.373.0779 Boehringer Ingelheim Investigational Site
Chiayi City
502.373.0783 Boehringer Ingelheim Investigational Site
Hualien City
502.373.0776 Boehringer Ingelheim Investigational Site
Kaohsiung City
502.373.0778 Boehringer Ingelheim Investigational Site
Kaohsiung City
502.373.0775 Boehringer Ingelheim Investigational Site
Tainan
502.373.0777 Boehringer Ingelheim Investigational Site
Tainan
502.373.0781 Boehringer Ingelheim Investigational Site
Taipei
502.373.0782 Boehringer Ingelheim Investigational Site
Taipei
Malaysia8 sites
502.373.0733 Boehringer Ingelheim Investigational Site
George Town
502.373.0736 Boehringer Ingelheim Investigational Site
Johor Bahru
502.373.0739 Boehringer Ingelheim Investigational Site
Kelantan
502.373.2707 Boehringer Ingelheim Investigational Site
Kelantan Darul Naim
502.373.0732 Boehringer Ingelheim Investigational Site
Kuala Lumpur
502.373.0734 Boehringer Ingelheim Investigational Site
Kuala Lumpur
502.373.60001 Boehringer Ingelheim Investigational Site
Kuala Selangor
502.373.0731 Boehringer Ingelheim Investigational Site
Putrajaya
New Zealand8 sites
502.373.0500 Boehringer Ingelheim Investigational Site
Auckland
502.373.0502 Boehringer Ingelheim Investigational Site
Auckland
502.373.0507 Boehringer Ingelheim Investigational Site
Christchurch
502.373.0504 Boehringer Ingelheim Investigational Site
Hamiton
502.373.0506 Boehringer Ingelheim Investigational Site
Hasting
502.373.0501 Middlemore Hospital
Otahuhu Auckland
502.373.0503 Boehringer Ingelheim Investigational Site
Takapuna Auckland
502.373.0505 Tauranga Study Centre
Tauranga
Thailand8 sites
502.373.0801 Boehringer Ingelheim Investigational Site
Bangkok
502.373.0802 Boehringer Ingelheim Investigational Site
Bangkok
502.373.0804 Boehringer Ingelheim Investigational Site
Bangkok
502.373.0805 Boehringer Ingelheim Investigational Site
Bangkok
502.373.0806 Boehringer Ingelheim Investigational Site
Bangkok
502.373.0808 Boehringer Ingelheim Investigational Site
Bangkok
502.373.0803 Boehringer Ingelheim Investigational Site
Khon Kaen
502.373.0807 Boehringer Ingelheim Investigational Site
Nonthaburi
Philippines6 sites
502.373.0702 De La Salle University Medical Center
Cavite
502.373.0700 Philippine General Hospital
Manila
502.373.0701 Manila Doctors Hospital, Room 3 Annex
Manila
502.373.0705 The Medical City
Pasig
502.373.0703 Philippine Heart Center
Quezon City
502.373.0704 National Kidney & Transplant Institute, Room 821
Quezon City
Austria5 sites
502.373.1128 Boehringer Ingelheim Investigational Site
Graz
502.373.1126 Boehringer Ingelheim Investigational Site
Vienna
502.373.1127 Boehringer Ingelheim Investigational Site
Vienna
502.373.1129 Boehringer Ingelheim Investigational Site
Vienna
502.373.1125 Boehringer Ingelheim Investigational Site
Wels
Hong Kong5 sites
502.373.0676 Boehringer Ingelheim Investigational Site
Hong Kong
502.373.0677 Boehringer Ingelheim Investigational Site
Hong Kong
502.373.0680 Boehringer Ingelheim Investigational Site
Hong Kong
502.373.0681 Boehringer Ingelheim Investigational Site
Hong Kong
502.373.0685 Boehringer Ingelheim Investigational Site
Hong Kong
Norway5 sites
502.373.20003 Boehringer Ingelheim Investigational Site
Fevik
502.373.20004 Fana Hjertesenter
Nesttun
502.373.20001 Stavanger Universitetssykehus
Stavanger
502.373.20005 Sykehuset i Vestfold, Avd. Tønsberg
Tønsberg
502.373.20002 Tvedestrand Legesenter
Tvedestrand
Puerto Rico5 sites
502.373.0215 Boehringer Ingelheim Investigational Site
Caguas
502.373.0267 Boehringer Ingelheim Investigational Site
Las Lomas
502.373.0190 Boehringer Ingelheim Investigational Site
Manati
502.373.0198 Boehringer Ingelheim Investigational Site
Orocovis
502.373.0262 Boehringer Ingelheim Investigational Site
Rio Piedras
Slovakia5 sites
502.373.1535 Boehringer Ingelheim Investigational Site
Bratislava
502.373.1529 Boehringer Ingelheim Investigational Site
Košice
502.373.1540 Boehringer Ingelheim Investigational Site
Košice
502.373.1538 Boehringer Ingelheim Investigational Site
Nitra
502.373.1545 Boehringer Ingelheim Investigational Site
Rimavská Sobota
Ireland4 sites
502.373.1714 Dept. of Clinical Pharmacology
Dublin
502.373.1717 Adelaide & Meath Hospitals
Dublin
502.373.1719 Pulmonary Function Laboratory
Dublin
502.373.1720 Mallow General Hospital
Mallow
United Arab Emirates4 sites
502.373.1680 Boehringer Ingelheim Investigational Site
Abu Dhabi
502.373.1675 Boehringer Ingelheim Investigational Site
Dubai
502.373.1679 Boehringer Ingelheim Investigational Site
Dubai
502.373.1677 Boehringer Ingelheim Investigational Site
Sharjah city
Singapore3 sites
502.373.2706 Boehringer Ingelheim Investigational Site
Kuala Lumpur
502.373.0725 Boehringer Ingelheim Investigational Site
Singapore
502.373.0726 Boehringer Ingelheim Investigational Site
Singapore
About this study
Official title: ONTARGET ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial A Large, Simple Randomized Trial of an Angiotensin II Receptor Antagonist (Telmisartan) and an ACE-Inhibitor (Ramipril) in Patients at High Risk for Cardiovascular Events and TRANSCEND Telmisartan Randomized AssessmeNt Study in aCE iNtolerant Subjects With Cardiovascular Disease. A Parallel Study Comparing the Effects of Telmisartan With Placebo and Outcomes in Patients at High Risk for Cardiovascular Events and Intolerant to ACE-I.
The Ongoing Telmisartan Alone and in combination wiht Ramipril Global Endpoint trial (ONTARGET): The primary objectives are to determine if (a) telmisartan 80mg daily and ramipril 10mg daily combination therapy is more effective in reducing the composite endpoint of Cardiovascular Death (CV) death, Myocardial infarction (MI), stroke or hospitalization for Congestive Heart Failure (CHF) compared with ramipril 10mg alone; and (b) telmisartan 80mg daily is at least as effective as (i.e. not less effective than) ramipril 10mg daily, on this endpoint.
Telmisartan Randomised Assessment Study in Angiotension converting Enzyme inhibitor intolerant subjects with Cardiovascular Disease. (TRANSCEND): The primary objective of the study is to determine if treatment with telmisartan 80mg daily is superior to placebo reducing the composite endpoint of Cardiovascular Death (CV), Myocardial Infarction ( MI)I, stroke or hospitalization for Congestive Heart Failure (CHF) in patients who are intolerant to Angiotension Converting Enzyme inhibitors.
- Conditions
- Cardiovascular Diseases
- Being tested
- Telmisartan, Combination of Telmisartan and Ramipril, Ramipril
- Medical subject headings
- Cardiovascular Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
TelmisartanDrug
Combination of Telmisartan and RamiprilDrug
RamiprilDrug
What is being measured
The primary outcome is the main question the study is designed to answer.
ONTARGET. Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction, Non-fatal Stroke and Hospitalization for Congestive Heart Failure
The Ongoing Telmisartan Alone and combination with Ramipril global Endpoint trial (ONTARGET). Time to first event analysis of the following defined endpoints, Cardiovascular Death, Non-fatal myocardial infarction, non-fatal stroke and hospitalization for congestive heart failure.
Measured: 56 months
ONTARGET. 3-fold Composite Endpoint of Doubling of Serum Creatinine, Progression to End Stage Renal Disease (ESRD) and All-cause Mortality in Diabetic Nephropathy Patients
ESRD is defined by initiation of dialysis, need for renal transplantation, or eGFR <15 mL/min/1.73 m². Diabetic nephropathy patients are diabetic patients with macro-albuminuria assessed as a Urinary Albumin Creatinine Ratio (UACR) ≥300 mg/g Crea at baseline.
These renal outcomes were not adjudicated (apart from death).
Measured: 56 months
TRANSCEND. Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction, Non-fatal Stroke and Hospitalization for Congestive Heart Failure
Telmisartan Randomized Assessment Study in Angiotension Converting Enzyme inhibitor intolerant subjects with cardiovascular disease (TRANSCEND). Time to first event analysis of the following defined endpoints, Cardiovascular Death, Non-fatal myocardial infarction, non-fatal stroke and hospitalization for congestive heart failure.
Measured: 56 months
Secondary outcomes (35)
ONTARGET. Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction and Non-fatal Stroke
The Ongoing Telmisartan Alone and combination with Ramipril global Endpoint trial (ONTARGET). Time to first event analysis of the following defined endpoints, non-fatal myocardial infarction or non-fatal stroke
Measured: 56 months
ONTARGET. Cardiovascular Death
The Ongoing Telmisartan Alone and combination with Ramipril global Endpoint trial (ONTARGET). Time to the first event analysis of the endpoint cardiovascular death.
Measured: 56 months
ONTARGET. Non-fatal Myocardial Infarction
The Ongoing Telmisartan Alone and combination with Ramipril global Endpoint trial (ONTARGET). Time to the first event analysis of the endpoint non-fatal myocardial infarction.
Measured: 56 months
ONTARGET. Non-fatal Stroke
The Ongoing Telmisartan Alone and combination with Ramipril global Endpoint trial (ONTARGET). Time to first event analysis of the endpoint non-fatal stroke.
Measured: 56 months
ONTARGET. Hospitalization for Congestive Heart Failure
The Ongoing Telmisartan Alone and combination with Ramipril global Endpoint trial (ONTARGET). Time to the first event analysis of the endpoint hospitalization for congestive heart failure.
Measured: 56 months
ONTARGET. Doubling of Serum Creatinine in Diabetic Nephropathy Patients
Diabetic nephropathy patients are diabetic patients with macro-albuminuria assessed as a Urinary Albumin Creatinine Ratio (UACR) ≥300 mg/g Crea at baseline.
Measured: 56 months
ONTARGET. Progression to End Stage Renal Disease (ESRD) in Diabetic Nephropathy Patients
ESRD is defined by initiation of dialysis, need for renal transplantation, or eGFR <15 mL/min/1.73 m². Diabetic nephropathy patients are diabetic patients with macro-albuminuria assessed as a Urinary Albumin Creatinine Ratio (UACR) ≥300 mg/g Crea at baseline.
Measured: 56 months
ONTARGET. All-cause Mortality in Diabetic Nephropathy Patients
Diabetic nephropathy patients are diabetic patients with macro-albuminuria assessed as a Urinary Albumin Creatinine Ratio (UACR) ≥300 mg/g Crea at baseline.
Measured: 56 months
ONTARGET. Doubling of Serum Creatinine
ONTARGET. Nephropathy subcategory: doubling of serum creatinine
Measured: 56 months
ONTARGET. Progression to ESRD
ONTARGET. Nephropathy subcategory: Progression to ESRD. Progression to ESRD is defined as initiation of dialysis, need for renal transplantation, or eGFR <15 mL/min/1.73 m².
Measured: 56 months
ONTARGET. New Microalbuminuria
ONTARGET. Nephropathy subcategory: New microalbuminuria. New microalbuminuria is defined as Urinary Albumin Creatinine Ratio ≥30 mg/g Crea in patients with a Urinary Albumin Creatinine Ratio <30 mg/g Crea at baseline.
Measured: 56 months
ONTARGET. New Macroalbuminuria
ONTARGET. Nephropathy subcategory: New macroalbuminuria. New macroalbuminuria is defined as Urinary Albumin Creatinine Ratio ≥300 mg/g Crea in patients with a Urinary Albumin Creatinine Ratio <300 mg/g Crea at baseline.
Measured: 56 months
ONTARGET. Combined Endpoint of Doubling of Serum Creatinine, Progression to ESRD, New Microalbuminuria, or New Macroalbuminuria
ONTARGET. Nephropathy subcategory: Combined endpoint of doubling of serum creatinine, progression to ESRD, new microalbuminuria, or new macroalbuminuria
Measured: 56 months
ONTARGET. Normalisation From Micro- or Macroalbuminuria to Normoalbuminuria
ONTARGET. Nephropathy subcategory: Normalisation from micro- or macroalbuminuria to normoalbuminuria. Normalisation from micro- or macroalbuminuria to normoalbuminuria is defined as UACR <30 mg/g Crea in patients with a UACR ≥30 mg/g Crea at baseline.
Measured: 56 months
ONTARGET. Newly Diagnosed Congestive Heart Failure
The Ongoing Telmisartan Alone and combination with Ramipril global Endpoint trial (ONTARGET). Time to the first event analysis of the endpoint Newly diagnosed Congestive Heart failure.
Measured: 56 months
ONTARGET. Cardiovascular Revascularization Procedure
The Ongoing Telmisartan Alone and combination with Ramipril global Endpoint trial (ONTARGET).
Measured: 56 months
ONTARGET. Newly Diagnosed Diabetes
The Ongoing Telmisartan Alone and combination with Ramipril global Endpoint trial (ONTARGET). Time to the first event analysis of the endpoint Newly diagnosed Diabetes. Only calculated for those patients without diabetes at baseline.
Measured: 56 months
ONTARGET. Cognitive Decline
The Ongoing Telmisartan Alone and combination with Ramipril global Endpoint trial (ONTARGET). Time to first event analysis of the endpoint cognitive decline i.e. Comparison of the Mini mental state Evaluation (MMSE) of patients at baseline with that at the 2years and end of trial. A decrease in MMSE from baseline represents a cognitive decline. This outcome measure is only available for those patients who had MMSE at baseline.
Measured: 56 months
ONTARGET. New Onset of Atrial Fibrillation
The Ongoing Telmisartan Alone and combination with Ramipril global Endpoint trial (ONTARGET). Time to first event analysis of endpoint new onset of atrial fibrillation.
Measured: 56 months
TRANSCEND. Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction and Non-fatal Stroke
Telmisartan Randomized Assessment Study in Angiotension Converting Enzyme inhibitor intolerant subjects with cardiovascular disease (TRANSCEND). Time to first event analysis of the following defined endpoints, Cardiovascular Death, Non-fatal myocardial infarction, non-fatal stroke and hospitalization for congestive heart failure.
Measured: 56 months
TRANSCEND. Cardiovascular Death
Telmisartan Randomized Assessment Study in Angiotension Converting Enzyme inhibitor intolerant subjects with cardiovascular disease (TRANSCEND). Time to the first event analysis of the endpoint cardiovascular death.
Measured: 56 months
TRANSCEND. Non-fatal Myocardial Infarction
Telmisartan Randomized Assessment Study in Angiotension Converting Enzyme inhibitor intolerant subjects with cardiovascular disease (TRANSCEND). Time to the first event analysis of the endpoint non-fatal myocardial infarction.
Measured: 56 months
TRANSCEND. Non-fatal Stroke
Telmisartan Randomized Assessment Study in Angiotension Converting Enzyme inhibitor intolerant subjects with cardiovascular disease (TRANSCEND).
Measured: 56 months
TRANSCEND. Hospitalization for Congestive Heart Failure
Telmisartan Randomized Assessment Study in Angiotension Converting Enzyme inhibitor intolerant subjects with cardiovascular disease (TRANSCEND).
Measured: 56 months
TRANSCEND. Doubling of Serum Creatinine
TRANSCEND. Nephropathy subcategory: doubling of serum creatinine
Measured: 56 months
TRANSCEND. Progression to ESRD
TRANSCEND. Nephropathy subcategory: Progression to ESRD. Progression to ESRD is defined as initiation of dialysis, need for renal transplantation, or eGFR <15 mL/min/1.73m²
Measured: 56 months
TRANSCEND. New Microalbuminuria
TRANSCEND. Nephropathy subcategory: New microalbuminuria. New microalbuminuria is defined as UACR ≥30 mg/g creatinine [Crea] in patients with a UACR <30 mg/g Crea at baseline
Measured: 56 months
TRANSCEND. New Macroalbuminuria
TRANSCEND. Nephropathy subcategory: New macroalbuminuria. New macroalbuminuria is defined as UACR ≥300 mg/g creatinine [Crea] in patients with a UACR <300 mg/g Crea at baseline
Measured: 56 months
TRANSCEND. Combined Endpoint of Doubling Serum Creatinine, Progression to ESRD, New Microalbuminuria or New Macroalbuminuria
TRANSCEND. Nephropathy subcategory: Combined endpoint of doubling serum creatinine, progression to ESRD, new microalbuminuria or new macroalbuminuria
Measured: 56 months
TRANSCEND. Normalisation From Micro- or Macroalbuminuria to Normoalbuminuria
TRANSCEND. Nephropathy subcategory: Normalisation from micro- or macroalbuminuria to normoalbuminuria. Normalisation from micro- or macroalbuminuria to normoalbuminuria is defined as UACR <30 mg/g Crea in patients with a UACR ≥30 mg/g Crea at baseline.
Measured: 56 months
TRANSCEND. New Onset of Atrial Fibrillation
Telmisartan Randomized Assessment Study in Angiotension Converting Enzyme inhibitor intolerant subjects with cardiovascular disease (TRANSCEND).
Measured: 56 months
TRANSCEND. Cognitive Decline
Telmisartan Randomized Assessment Study in Angiotension Converting Enzyme inhibitor intolerant subjects with cardiovascular disease (TRANSCEND). Time to first event analysis of the endpoint cognitive decline i.e. Comparison of the Mini mental state Evaluation (MMSE) of patients at baseline with that at the 2years and end of trial. A decrease in MMSE from baseline represents a cognitive decline. This outcome measure is only available for those patients who had MMSE at baseline.
Measured: 56 months
TRANSCEND. Newly Diagnosed Diabetes
Telmisartan Randomized Assessment Study in Angiotension Converting Enzyme inhibitor intolerant subjects with cardiovascular disease (TRANSCEND). Time to the first event analysis of the endpoint Newly diagnosed Diabetes. Only calculated for those patients without diabetes at baseline.
Measured: 56 months
TRANSCEND. Cardiovascular Revascularization Procedure
Telmisartan Randomized Assessment Study in Angiotension Converting Enzyme inhibitor intolerant subjects with cardiovascular disease (TRANSCEND).
Measured: 56 months
TRANSCEND. Newly Diagnosed Congestive Heart Failure
Telmisartan Randomized Assessment Study in Angiotension Converting Enzyme inhibitor intolerant subjects with cardiovascular disease (TRANSCEND).
Measured: 56 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Sep 2005 (estimated)
- Study startNov 2001
- Primary completionJun 2008
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (39)Papers the sponsor has linked to this study.
- Other trials for Cardiovascular DiseasesStudies of the same condition, open and under way.
- More trials run by Boehringer IngelheimThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Prevention
- Intervention model
- Parallel groups
- Enrolment
- 31,546 participants (actual)
Sponsor and investigators
- Lead sponsor
- Boehringer Ingelheim
- Sponsor type
- Industry (pharma, biotech, devices)
- Investigators
- Boehringer Ingelheim, Study chair, Boehringer Ingelheim
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00153101
- Sponsor's protocol ID
- 502.373
- Status last verified
- May 2014
- First submitted
- 9 Sep 2005
- Last updated
- 20 May 2014
- Results posted
- Yes, on ClinicalTrials.gov
Publications
Lee SF, Ramasundarahettige C, Gerstein HC, McIntyre WF, Eikelboom J, O'Donnell MJ, Zhou Y, Bangdiwala SI, Thabane L. Comparison of total event analysis and first event analysis in relation to heterogeneity in cardiovascular trials. BMC Med Res Methodol. 2025 Jun 9;25(1):159. doi: 10.1186/s12874-025-02593-3.
PubMed 40490702Natale P, Palmer SC, Navaneethan SD, Craig JC, Strippoli GF. Angiotensin-converting-enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev. 2024 Apr 29;4(4):CD006257. doi: 10.1002/14651858.CD006257.pub2.
PubMed 38682786Haring B, Schumacher H, Mancia G, Teo KK, Lonn EM, Mahfoud F, Schmieder R, Mann JFE, Sliwa K, Yusuf S, Bohm M. Triglyceride-glucose index, low-density lipoprotein levels, and cardiovascular outcomes in chronic stable cardiovascular disease: results from the ONTARGET and TRANSCEND trials. Eur J Prev Cardiol. 2024 Feb 15;31(3):311-319. doi: 10.1093/eurjpc/zwad340.
PubMed 37890035Cooper TE, Teng C, Tunnicliffe DJ, Cashmore BA, Strippoli GF. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease. Cochrane Database Syst Rev. 2023 Jul 19;7(7):CD007751. doi: 10.1002/14651858.CD007751.pub3.
PubMed 37466151Bohm M, Schumacher H, Werner C, Teo KK, Lonn EM, Mahfoud F, Speer T, Mancia G, Redon J, Schmieder RE, Sliwa K, Marx N, Weber MA, Laufs U, Williams B, Yusuf S, Mann JFE. Association between exercise frequency with renal and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk. Cardiovasc Diabetol. 2022 Jan 20;21(1):12. doi: 10.1186/s12933-021-01429-w.
PubMed 35057807Bohm M, Schumacher H, Teo KK, Lonn EM, Lauder L, Mancia G, Redon J, Schmieder RE, Sliwa K, Marx N, Weber MA, Williams B, Yusuf S, Mann JFE, Mahfoud F. Cardiovascular outcomes in patients at high cardiovascular risk with previous myocardial infarction or stroke. J Hypertens. 2021 Aug 1;39(8):1602-1610. doi: 10.1097/HJH.0000000000002822.
PubMed 34188004Bohm M, Schumacher H, Teo KK, Lonn EM, Mahfoud F, Emrich I, Mancia G, Redon J, Schmieder RE, Sliwa K, Lehrke M, Marx N, Weber MA, Williams B, Yusuf S, Mann JFE. Renal outcomes and blood pressure patterns in diabetic and nondiabetic individuals at high cardiovascular risk. J Hypertens. 2021 Apr 1;39(4):766-774. doi: 10.1097/HJH.0000000000002697.
PubMed 33560052Mancia G, Schumacher H, Bohm M, Mann JFE, Redon J, Facchetti R, Schmieder RE, Lonn EM, Teo KK, Yusuf S. Visit-to-visit blood pressure variability and renal outcomes: results from ONTARGET and TRANSCEND trials. J Hypertens. 2020 Oct;38(10):2050-2058. doi: 10.1097/HJH.0000000000002567.
PubMed 32890282Dehghan M, Mente A, Rangarajan S, Mohan V, Lear S, Swaminathan S, Wielgosz A, Seron P, Avezum A, Lopez-Jaramillo P, Turbide G, Chifamba J, AlHabib KF, Mohammadifard N, Szuba A, Khatib R, Altuntas Y, Liu X, Iqbal R, Rosengren A, Yusuf R, Smuts M, Yusufali A, Li N, Diaz R, Yusoff K, Kaur M, Soman B, Ismail N, Gupta R, Dans A, Sheridan P, Teo K, Anand SS, Yusuf S. Association of egg intake with blood lipids, cardiovascular disease, and mortality in 177,000 people in 50 countries. Am J Clin Nutr. 2020 Apr 1;111(4):795-803. doi: 10.1093/ajcn/nqz348.
PubMed 31965140Bohm M, Schumacher H, Teo KK, Lonn EM, Mahfoud F, Mann JFE, Mancia G, Redon J, Schmieder RE, Marx N, Sliwa K, Weber MA, Williams B, Yusuf S. Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk. Eur Heart J. 2019 Jul 1;40(25):2032-2043. doi: 10.1093/eurheartj/ehz149.
PubMed 30919899Bohm M, Schumacher H, Teo KK, Lonn EM, Mahfoud F, Ukena C, Mann JFE, Mancia G, Redon J, Schmieder RE, Sliwa K, Marx N, Weber MA, Williams B, Yusuf S. Resting heart rate and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk analysis from the ONTARGET/TRANSCEND trials. Eur Heart J. 2020 Jan 7;41(2):231-238. doi: 10.1093/eurheartj/ehy808.
PubMed 30590564Bohm M, Schumacher H, Teo KK, Lonn EM, Mahfoud F, Mann JFE, Mancia G, Redon J, Schmieder RE, Sliwa K, Weber MA, Williams B, Yusuf S. Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. Lancet. 2017 Jun 3;389(10085):2226-2237. doi: 10.1016/S0140-6736(17)30754-7. Epub 2017 Apr 5.
PubMed 28390695Dunkler D, Kohl M, Teo KK, Heinze G, Dehghan M, Clase CM, Gao P, Yusuf S, Mann JF, Oberbauer R. Dietary risk factors for incidence or progression of chronic kidney disease in individuals with type 2 diabetes in the European Union. Nephrol Dial Transplant. 2015 Aug;30 Suppl 4:iv76-85. doi: 10.1093/ndt/gfv086.
PubMed 26209742Bohm M, Schumacher H, Leong D, Mancia G, Unger T, Schmieder R, Custodis F, Diener HC, Laufs U, Lonn E, Sliwa K, Teo K, Fagard R, Redon J, Sleight P, Anderson C, O'Donnell M, Yusuf S. Systolic blood pressure variation and mean heart rate is associated with cognitive dysfunction in patients with high cardiovascular risk. Hypertension. 2015 Mar;65(3):651-61. doi: 10.1161/HYPERTENSIONAHA.114.04568. Epub 2015 Jan 12.
PubMed 25583157Verdecchia P, Reboldi G, Angeli F, Trimarco B, Mancia G, Pogue J, Gao P, Sleight P, Teo K, Yusuf S. Systolic and diastolic blood pressure changes in relation with myocardial infarction and stroke in patients with coronary artery disease. Hypertension. 2015 Jan;65(1):108-14. doi: 10.1161/HYPERTENSIONAHA.114.04310. Epub 2014 Oct 20.
PubMed 25331850
Study at a glance
From the registry record, last updated by the sponsor on 20 May 2014. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- ONTARGET ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial A Large, Simple Randomized Trial of an Angiotensin II Receptor Antagonist (Telmisartan) and an ACE-Inhibitor (Ramipril) in Patients at High Risk for Cardiovascular Events and TRANSCEND Telmisartan Randomized AssessmeNt Study in aCE iNtolerant Subjects With Cardiovascular Disease. A Parallel Study Comparing the Effects of Telmisartan With Placebo and Outcomes in Patients at High Risk for Cardiovascular Events and Intolerant to ACE-I.
- ClinicalTrials.gov ID
- NCT00153101
- Acronym / sponsor ID
- 502.373
- Conditions
- Cardiovascular Diseases
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 31,546 participants (actual)
- Lead sponsor
- Boehringer IngelheimIndustry (pharma, biotech, devices)
- Study start
- Nov 2001
- Primary completion
- Jun 2008 (actual)
- First posted
- 12 Sep 2005 (estimated)
- Results
- Posted 25 Aug 2009
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The Ongoing Telmisartan Alone and in combination wiht Ramipril Global Endpoint trial (ONTARGET): The primary objectives are to determine if (a) telmisartan 80mg daily and ramipril 10mg daily combination therapy is more effective in reducing the composite endpoint of Cardiovascular Death (CV) death, Myocardial infarction (MI), stroke or hospitalization for Congestive Heart Failure (CHF) compared with ramipril 10mg alone; and (b) telmisartan 80mg daily is at least as effective as (i.e. not less effective than) ramipril 10mg daily, on this endpoint.
Telmisartan Randomised Assessment Study in Angiotension converting Enzyme inhibitor intolerant subjects with Cardiovascular Disease. (TRANSCEND): The primary objective of the study is to determine if treatment with telmisartan 80mg daily is superior to placebo reducing the composite endpoint of Cardiovascular Death (CV), Myocardial Infarction ( MI)I, stroke or hospitalization for Congestive Heart Failure (CHF) in patients who are intolerant to Angiotension Converting Enzyme inhibitors.
Study design
- Primary purpose
- Prevention
- Intervention model
- Parallel groups
Who may qualify
- Ages
- 55 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Coronary Artery Disease: Previous Myocardial infarction(> 2 days prior to informed consent), or stable or previous unstable angina (> 30 days prior to informed consent) with documented multivessel coronary artery disease or a positive stress test, or multivessel Percutaneous Transluminal Coronary Angioplasty (> 30 days prior to informed consent), or previous multivessel Coronary Artery Bypass Grafting without angina (if surgery performed > 4 years prior to informed consent) or with recurrent angina after surgery.
- Peripheral Arterial Disease: Previous limb bypass surgery or angioplasty or amputation, intermittent claudication on history with ankle/arm Blood Pressure ratio < 0.8 on at least one side, or significant stenosis by angiography or non-invasive testing
- Previous stroke
- Transient ischemic Attack > 7 days and < 1 year prior to informed consent
- Diabetes Mellitus (types I or II): with evidence of end-organ damage (retinopathy, Left ventricular hypertrophy, micro or macro albuminuria), or any evidence of previous cardiac or vascular disease.
Key exclusion criteria (29 listed)
- Medication use:
- Inability to discontinue Angiotension Converting Enzyme (ACE) inhibitors or Angiotension 2 receptor antagonists (AIIAs).
- Patients with known hypersensitivity or intolerance to Angiotension 2 receptor antagonists (AIIAs) or Angiotension Converting Enzyme (ACE)inhibitors.
- NOTE: Patients with known intolerance to Angiotension Converting Enzyme inhibitor intolerance ( ACE-I) can be enrolled in the TRANSCEND study.
- Cardiovascular disease:
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Telmisartan | Drug | – |
| Combination of Telmisartan and Ramipril | Drug | – |
| Ramipril | Drug | – |
Primary outcome
ONTARGET. Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction, Non-fatal Stroke and Hospitalization for Congestive Heart Failure
Time frame: 56 months
The Ongoing Telmisartan Alone and combination with Ramipril global Endpoint trial (ONTARGET). Time to first event analysis of the following defined endpoints, Cardiovascular Death, Non-fatal myocardial infarction, non-fatal stroke and hospitalization for congestive heart failure.
ONTARGET. 3-fold Composite Endpoint of Doubling of Serum Creatinine, Progression to End Stage Renal Disease (ESRD) and All-cause Mortality in Diabetic Nephropathy Patients
Time frame: 56 months
ESRD is defined by initiation of dialysis, need for renal transplantation, or eGFR <15 mL/min/1.73 m². Diabetic nephropathy patients are diabetic patients with macro-albuminuria assessed as a Urinary Albumin Creatinine Ratio (UACR) ≥300 mg/g Crea at baseline. These renal outcomes were not adjudicated (apart from death).
TRANSCEND. Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction, Non-fatal Stroke and Hospitalization for Congestive Heart Failure
Time frame: 56 months
Telmisartan Randomized Assessment Study in Angiotension Converting Enzyme inhibitor intolerant subjects with cardiovascular disease (TRANSCEND). Time to first event analysis of the following defined endpoints, Cardiovascular Death, Non-fatal myocardial infarction, non-fatal stroke and hospitalization for congestive heart failure.
35 secondary outcomes
ONTARGET. Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction and Non-fatal Stroke
Time frame: 56 months
ONTARGET. Cardiovascular Death
Time frame: 56 months
ONTARGET. Non-fatal Myocardial Infarction
Time frame: 56 months
ONTARGET. Non-fatal Stroke
Time frame: 56 months
ONTARGET. Hospitalization for Congestive Heart Failure
Time frame: 56 months
ONTARGET. Doubling of Serum Creatinine in Diabetic Nephropathy Patients
Time frame: 56 months
ONTARGET. Progression to End Stage Renal Disease (ESRD) in Diabetic Nephropathy Patients
Time frame: 56 months
ONTARGET. All-cause Mortality in Diabetic Nephropathy Patients
Time frame: 56 months
ONTARGET. Doubling of Serum Creatinine
Time frame: 56 months
ONTARGET. Progression to ESRD
Time frame: 56 months
ONTARGET. New Microalbuminuria
Time frame: 56 months
ONTARGET. New Macroalbuminuria
Time frame: 56 months
ONTARGET. Combined Endpoint of Doubling of Serum Creatinine, Progression to ESRD, New Microalbuminuria, or New Macroalbuminuria
Time frame: 56 months
ONTARGET. Normalisation From Micro- or Macroalbuminuria to Normoalbuminuria
Time frame: 56 months
ONTARGET. Newly Diagnosed Congestive Heart Failure
Time frame: 56 months
ONTARGET. Cardiovascular Revascularization Procedure
Time frame: 56 months
ONTARGET. Newly Diagnosed Diabetes
Time frame: 56 months
ONTARGET. Cognitive Decline
Time frame: 56 months
ONTARGET. New Onset of Atrial Fibrillation
Time frame: 56 months
TRANSCEND. Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction and Non-fatal Stroke
Time frame: 56 months
TRANSCEND. Cardiovascular Death
Time frame: 56 months
TRANSCEND. Non-fatal Myocardial Infarction
Time frame: 56 months
TRANSCEND. Non-fatal Stroke
Time frame: 56 months
TRANSCEND. Hospitalization for Congestive Heart Failure
Time frame: 56 months
TRANSCEND. Doubling of Serum Creatinine
Time frame: 56 months
TRANSCEND. Progression to ESRD
Time frame: 56 months
TRANSCEND. New Microalbuminuria
Time frame: 56 months
TRANSCEND. New Macroalbuminuria
Time frame: 56 months
TRANSCEND. Combined Endpoint of Doubling Serum Creatinine, Progression to ESRD, New Microalbuminuria or New Macroalbuminuria
Time frame: 56 months
TRANSCEND. Normalisation From Micro- or Macroalbuminuria to Normoalbuminuria
Time frame: 56 months
TRANSCEND. New Onset of Atrial Fibrillation
Time frame: 56 months
TRANSCEND. Cognitive Decline
Time frame: 56 months
TRANSCEND. Newly Diagnosed Diabetes
Time frame: 56 months
TRANSCEND. Cardiovascular Revascularization Procedure
Time frame: 56 months
TRANSCEND. Newly Diagnosed Congestive Heart Failure
Time frame: 56 months
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 May 2014.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 40490702Lee SF, Ramasundarahettige C, Gerstein HC, McIntyre WF, Eikelboom J, O'Donnell MJ, Zhou Y, Bangdiwala SI, Thabane L. Comparison of total event analysis and first event analysis in relation to heterogeneity in cardiovascular trials. BMC Med Res Methodol. 2025 Jun 9;25(1):159. doi: 10.1186/s12874-025-02593-3.
- Derived from this study: PubMed 38682786Natale P, Palmer SC, Navaneethan SD, Craig JC, Strippoli GF. Angiotensin-converting-enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev. 2024 Apr 29;4(4):CD006257. doi: 10.1002/14651858.CD006257.pub2.
- Derived from this study: PubMed 37890035Haring B, Schumacher H, Mancia G, Teo KK, Lonn EM, Mahfoud F, Schmieder R, Mann JFE, Sliwa K, Yusuf S, Bohm M. Triglyceride-glucose index, low-density lipoprotein levels, and cardiovascular outcomes in chronic stable cardiovascular disease: results from the ONTARGET and TRANSCEND trials. Eur J Prev Cardiol. 2024 Feb 15;31(3):311-319. doi: 10.1093/eurjpc/zwad340.
- Derived from this study: PubMed 37466151Cooper TE, Teng C, Tunnicliffe DJ, Cashmore BA, Strippoli GF. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease. Cochrane Database Syst Rev. 2023 Jul 19;7(7):CD007751. doi: 10.1002/14651858.CD007751.pub3.
- Derived from this study: PubMed 35057807Bohm M, Schumacher H, Werner C, Teo KK, Lonn EM, Mahfoud F, Speer T, Mancia G, Redon J, Schmieder RE, Sliwa K, Marx N, Weber MA, Laufs U, Williams B, Yusuf S, Mann JFE. Association between exercise frequency with renal and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk. Cardiovasc Diabetol. 2022 Jan 20;21(1):12. doi: 10.1186/s12933-021-01429-w.
- Derived from this study: PubMed 34188004Bohm M, Schumacher H, Teo KK, Lonn EM, Lauder L, Mancia G, Redon J, Schmieder RE, Sliwa K, Marx N, Weber MA, Williams B, Yusuf S, Mann JFE, Mahfoud F. Cardiovascular outcomes in patients at high cardiovascular risk with previous myocardial infarction or stroke. J Hypertens. 2021 Aug 1;39(8):1602-1610. doi: 10.1097/HJH.0000000000002822.
- Derived from this study: PubMed 33560052Bohm M, Schumacher H, Teo KK, Lonn EM, Mahfoud F, Emrich I, Mancia G, Redon J, Schmieder RE, Sliwa K, Lehrke M, Marx N, Weber MA, Williams B, Yusuf S, Mann JFE. Renal outcomes and blood pressure patterns in diabetic and nondiabetic individuals at high cardiovascular risk. J Hypertens. 2021 Apr 1;39(4):766-774. doi: 10.1097/HJH.0000000000002697.
- Derived from this study: PubMed 32890282Mancia G, Schumacher H, Bohm M, Mann JFE, Redon J, Facchetti R, Schmieder RE, Lonn EM, Teo KK, Yusuf S. Visit-to-visit blood pressure variability and renal outcomes: results from ONTARGET and TRANSCEND trials. J Hypertens. 2020 Oct;38(10):2050-2058. doi: 10.1097/HJH.0000000000002567.
- Derived from this study: PubMed 31965140Dehghan M, Mente A, Rangarajan S, Mohan V, Lear S, Swaminathan S, Wielgosz A, Seron P, Avezum A, Lopez-Jaramillo P, Turbide G, Chifamba J, AlHabib KF, Mohammadifard N, Szuba A, Khatib R, Altuntas Y, Liu X, Iqbal R, Rosengren A, Yusuf R, Smuts M, Yusufali A, Li N, Diaz R, Yusoff K, Kaur M, Soman B, Ismail N, Gupta R, Dans A, Sheridan P, Teo K, Anand SS, Yusuf S. Association of egg intake with blood lipids, cardiovascular disease, and mortality in 177,000 people in 50 countries. Am J Clin Nutr. 2020 Apr 1;111(4):795-803. doi: 10.1093/ajcn/nqz348.
- Derived from this study: PubMed 30919899Bohm M, Schumacher H, Teo KK, Lonn EM, Mahfoud F, Mann JFE, Mancia G, Redon J, Schmieder RE, Marx N, Sliwa K, Weber MA, Williams B, Yusuf S. Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk. Eur Heart J. 2019 Jul 1;40(25):2032-2043. doi: 10.1093/eurheartj/ehz149.
- Derived from this study: PubMed 30590564Bohm M, Schumacher H, Teo KK, Lonn EM, Mahfoud F, Ukena C, Mann JFE, Mancia G, Redon J, Schmieder RE, Sliwa K, Marx N, Weber MA, Williams B, Yusuf S. Resting heart rate and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk analysis from the ONTARGET/TRANSCEND trials. Eur Heart J. 2020 Jan 7;41(2):231-238. doi: 10.1093/eurheartj/ehy808.
- Derived from this study: PubMed 28390695Bohm M, Schumacher H, Teo KK, Lonn EM, Mahfoud F, Mann JFE, Mancia G, Redon J, Schmieder RE, Sliwa K, Weber MA, Williams B, Yusuf S. Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. Lancet. 2017 Jun 3;389(10085):2226-2237. doi: 10.1016/S0140-6736(17)30754-7. Epub 2017 Apr 5.
- Related InfoLink provided by the sponsor.
Related trials for Cardiovascular Diseases
Active, not recruitingPhase 3
ENDOTHELION Study Group: Effect of Bosentan in NAION Patients
Ischemic Optic Neuropathy
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Not yet recruitingPhase 2
Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma (RRMM)
RecruitingPhase 2
Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)
Multiple Myeloma
Recruiting
PAW-Hydrogel for Chronic Wound Healing
Diabetic Foot Ulcer (DFU), Pressure Ulcer (PU)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Boehringer Ingelheim study chair
Boehringer Ingelheim
732 sites in 41 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Telmisartan, Combination of Telmisartan and Ramipril and Ramipril in people with Cardiovascular Diseases, run by Boehringer Ingelheim at 732 sites in 41 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 29 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 20 May 2014. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 732 sites in United States, Canada, Germany, Australia, China and 36 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 25 Aug 2009). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
ONTARGET. Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction, Non-fatal Stroke and Hospitalization for Congestive Heart Failure (time frame: 56 months). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00153101, which also lists 39 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 May 2014.